{"analyses":[{"ciLowerLimit":"0.556","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.870","estimateComment":"Stratified Cox Proportional Model","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0014","paramType":"Hazard Ratio (HR)","paramValue":"0.70","statisticalComment":"Stratified Log-Rank Test","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.06","upperLimit":"6.67","value":"5.6"},{"groupId":"OG001","lowerLimit":"3.98","upperLimit":"5.39","value":"4.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"177"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Margetuximab 15 mg/kg administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens.","id":"OG000","title":"Margetuximab Plus Chemotherapy"},{"description":"Trastuzumab administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens.","id":"OG001","title":"Trastuzumab Plus Chemotherapy"},{"description":"Margetuximab with or without chemotherapy","id":"OG002","title":"Margetuximab Infusion Substudy"}],"paramType":"MEDIAN","populationDescription":"Analysis population consisted of all patient who had investigator-assessed responses to treatment as of the interim analysis. The outcome measure is calculated only for the randomized study population. The 88 participants in the sub-study were not part of the efficacy population.","reportingStatus":"POSTED","timeFrame":"Tumor assessments are conducted every 6 weeks for the first 24 weeks and then every 24 weeks until progression of cancer, up to 6.5 years.","title":"To Evaluate Progression-free Survival (PFS), as Assessed by Study Investigators.","type":"SECONDARY","unitOfMeasure":"months"}